

1

2 **Analysis of 1,25-dihydroxyvitamin D<sub>3</sub> genomic action reveals calcium regulating and**  
3 **calcium independent effects in mouse intestine and human enteroids**

4

5

6

7 Shanshan Li<sup>1</sup>, Jessica De La Cruz<sup>1</sup>, Steven Hutchens<sup>2</sup>, Somshuvra Mukhopadhyay<sup>2</sup>, Zachary K.  
8 Criss<sup>3</sup>, Rohit Aita<sup>4</sup>, Oscar Pellon-Cardenas<sup>4</sup>, Joseph Hur<sup>4</sup>, Patricia Soteropoulos<sup>1,5</sup>, Seema  
9 Husain<sup>1,5</sup>, Puneet Dhawan<sup>1,5</sup>, Lieve Verlinden<sup>6</sup>, Geert Carmeliet<sup>6</sup>, James C. Fleet<sup>7</sup>, Noah F.  
10 Shroyer<sup>3</sup>, Michael P. Verzi<sup>4</sup> and Sylvia Christakos<sup>1\*</sup>

11

12

13 <sup>1</sup>Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers, The State  
14 University of New Jersey, New Jersey Medical School, Newark, New Jersey 07103, <sup>2</sup>Division of  
15 Pharmacology and Toxicology, College of Pharmacy, Institute for Cellular and Molecular  
16 Biology and Institute for Neuroscience, The University of Texas at Austin, Austin, Texas 78712,  
17 <sup>3</sup>Integrative Molecular and Biomedical Sciences Graduate Program, Division of Medicine,  
18 Baylor College of Medicine, Houston, Texas 77030, <sup>4</sup>Department of Genetics, Rutgers  
19 University, New Brunswick, New Jersey 08854, <sup>5</sup>Genomics Center, Rutgers, The State  
20 University of New Jersey, New Jersey Medical School, Newark, New Jersey 07103, <sup>6</sup>Laboratory  
21 of Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism,  
22 Leuven, Belgium, <sup>7</sup>Department of Nutrition Science, Purdue University, West Lafayette, Indiana  
23 47907

24

25

26

\*Corresponding author: Dr. Sylvia Christakos

27

E-mail: [christak@njms.rutgers.edu](mailto:christak@njms.rutgers.edu)

28

**Running title:** 1,25(OH)<sub>2</sub>D<sub>3</sub> gene regulation in mouse and human intestine

29

30

31

32

33

**Keywords:** calcium, manganese, transporters, intestine, vitamin D, human enteroids, mouse,  
34 Slc30a10, TRPV6

35

36

37 **Abstract**

38 Although vitamin D is critical for the function of the intestine, most studies have focused on the  
39 duodenum. We show that transgenic expression of the vitamin D receptor (VDR) only in the  
40 distal intestine of VDR null mice (KO/TG mice) results in the normalization of serum calcium  
41 and rescue of rickets. Although it had been suggested that calcium transport in the distal  
42 intestine involves a paracellular process, we found that the 1,25(OH)<sub>2</sub>D<sub>3</sub> activated genes in the  
43 proximal intestine associated with active calcium transport (*Trpv6*, *S100g*, *Atp2b1*) are also  
44 induced by 1,25(OH)<sub>2</sub>D<sub>3</sub> in the distal intestine of KO/TG mice. In addition, *Slc30a10*, a  
45 manganese efflux transporter, was one of the genes most induced by 1,25(OH)<sub>2</sub>D<sub>3</sub> in both  
46 proximal and distal intestine. Both villus and crypt were found to express *Vdr* and VDR target  
47 genes. RNA-seq analysis of human enteroids indicated that the effects of 1,25(OH)<sub>2</sub>D<sub>3</sub> observed  
48 in mice are conserved in humans. Using *Slc30a10*<sup>-/-</sup> mice, a loss of cortical bone and a marked  
49 decrease in *S100g* and *Trpv6* in the intestine was observed. Our findings suggest an  
50 interrelationship between vitamin D and intestinal Mn efflux and indicate the importance of  
51 distal intestinal segments to vitamin D action.

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68 **Introduction**

69

70 The essential role of vitamin D is to mediate calcium homeostasis through its regulatory  
71 effects on intestine, bone and kidney (1). Vitamin D has also been reported to affect numerous  
72 other physiological processes not involved in calcium regulation including immunomodulatory  
73 effects and inhibition of cancer progression (1). The skeletal and extraskeletal effects of  
74  $1,25(\text{OH})_2\text{D}_3$  (the biologically active form of vitamin D; calcitriol) are mediated by the vitamin  
75 D receptor (VDR), a nuclear protein which heterodimerizes with the retinoid X receptor (RXR).  
76 VDR/RXR interacts with DNA sequences, vitamin D response elements (VDREs) in target  
77 genes and leads to activation or repression of transcription.  $1,25(\text{OH})_2\text{D}_3$  also recruits  
78 coregulatory complexes that participate in the regulation of transcription of VDR target genes.  
79 VDR-mediated gene transcription is a multi-step process requiring the spatial and sequential  
80 combination of transcriptional coactivators and is influenced by the particular subcellular  
81 environment in a gene specific manner (2,3).

82

83 A principal target tissue of vitamin D action is the intestine (1,4,5). However, little is  
84 known about the molecular targets mediating the effects of vitamin D on intestinal biology. The  
85 classic role of  $1,25(\text{OH})_2\text{D}_3$  is regulation of intestinal calcium absorption which is crucial for  
86 bone health. When the need for calcium increases, for example during periods of habitual low  
87 calcium intake and during growth, vitamin D mediated intestinal calcium absorption occurs  
88 predominantly by an active transcellular process. The most pronounced effects of  $1,25(\text{OH})_2\text{D}_3$   
89 during the active calcium transport process are increased synthesis of the epithelial calcium  
90 channel TRPV6 and the intracellular calcium binding protein calbindin- $\text{D}_{9k}$  (4,5). In addition to  
91 the active transcellular pathway, calcium can also be absorbed via a non-saturable paracellular  
92 process (4,5). Whether  $1,25(\text{OH})_2\text{D}_3$  regulates calcium absorption by modulating genes  
93 associated solely with the facilitated diffusion model or whether  $1,25(\text{OH})_2\text{D}_3$  affects the  
94 paracellular process has been a matter of debate (6-9). Most research on calcium absorption has  
95 utilized the proximal small intestine and early studies reported that  $1,25(\text{OH})_2\text{D}_3$  regulated active  
96 calcium transport was localized only in the duodenum (9). It had been suggested that calcium

97 absorption in the distal intestine reflects vitamin D independent passive diffusion (10). However  
98 previous studies also noted that  $1,25(\text{OH})_2\text{D}_3$  and low dietary calcium can regulate active  
99 calcium absorption in the distal intestine of rats (11-13). In addition, we recently showed that  
100 transgenic expression of VDR only in the distal intestine (distal ileum, cecum and colon) at  
101 levels equivalent to wild type (WT) mice results in normal calcium homeostasis and reverses the  
102 VDR dependent rickets of the VDR null mice (14). These findings indicate the importance of the  
103 distal intestinal segments to vitamin D action.

104 Although the classical intestinal role of  $1,25(\text{OH})_2\text{D}_3$  is regulation of calcium absorption,  
105  $1,25(\text{OH})_2\text{D}_3$  has been reported to have other important effects on the intestine including  
106 protection of the integrity of the mucosal barrier, regulation of pathogen invasion, apoptosis,  
107 nutrient transport and cellular differentiation (7,15-19). However, the molecular responses to  
108  $1,25(\text{OH})_2\text{D}_3$  resulting in these effects in proximal vs. distal intestine are poorly understood. In  
109 addition, although intestinal epithelial cells at the villi have been identified as targets for  
110  $1,25(\text{OH})_2\text{D}_3$ , little is known about the effect of  $1,25(\text{OH})_2\text{D}_3$  in crypts and whether  $1,25(\text{OH})_2\text{D}_3$   
111 responses occur in crypts has been a matter of debate (20-22). Thus, the diversity and complexity  
112 of vitamin D signaling in the intestine have not been fully clarified.

113 In this study in order to further understand the role of vitamin D in the intestine, we  
114 examined the expression of VDR targets using transgenic mice with expression of VDR  
115 restricted to the distal intestine (KO/TG mice) (14) and compared our findings in these  
116 transgenic mice to vitamin D targets in both proximal and distal intestine of vitamin D deficient  
117 mice treated with  $1,25(\text{OH})_2\text{D}_3$ . The classic  $1,25(\text{OH})_2\text{D}_3$  activated genes found in the proximal  
118 intestine and associated with active calcium transport (*Trpv6*, *S100g*, *Atp2b1*) were also induced  
119 in the distal intestine. In addition, one of the genes most induced by  $1,25(\text{OH})_2\text{D}_3$  in the proximal  
120 and distal intestine was *Slc30a10*, a manganese (Mn) efflux transporter which has recently been  
121 found to be critical for protection against neurotoxicity and liver injury which occur in the  
122 presence of elevated Mn levels (23). Both villus and crypts were found to express high levels of  
123 VDR and result in  $1,25(\text{OH})_2\text{D}_3$  mediated target gene induction. RNA-seq analysis of human  
124 enteroids confirmed the induction of the same genes in mice and humans (*TRPV6*, *SLC30A10*,  
125 *ATP2B1* and *CYP24A1*) in both villus and crypts indicating for the first time direct  
126 transcriptomic responses to  $1,25(\text{OH})_2\text{D}_3$  in human enteroids in both crypt and villus-like

127 compartments. Studies in *Slc30a10*<sup>-/-</sup> mice showed a loss of cortical bone and a marked decrease  
128 in *Sl00g* and *Trpv6* in the intestine of these mice. Our findings suggest that 1,25(OH)<sub>2</sub>D<sub>3</sub> may  
129 have a role not only to maintain calcium homeostasis but also in the cellular homeostasis of other  
130 divalent ions. Our findings emphasize the importance of the distal as well as the proximal  
131 intestine in order to understand intestinal effects of 1,25(OH)<sub>2</sub>D<sub>3</sub> and that the effects of  
132 1,25(OH)<sub>2</sub>D<sub>3</sub> involve intestinal epithelial cells in both villus and crypt.

133

## 134 **Results**

### 135 **RNA-seq Analysis of Transcriptomic Responses to 1,25(OH)<sub>2</sub>D<sub>3</sub> in the Colon of Mice with** 136 **Transgenic Expression of VDR Only in the Distal Intestine**

137 Although most studies have focused on calcium absorption in the proximal intestine, our  
138 previous study demonstrated that transgenic expression of VDR only in the distal intestine  
139 rescued VDR-dependent rickets observed in the VDR KO mouse. To understand mechanisms by  
140 which 1,25(OH)<sub>2</sub>D<sub>3</sub> acts to regulate intestinal biology not only in the proximal but also in the  
141 distal intestine, transcriptomic profiling was done to examine the expression of genes induced by  
142 1,25(OH)<sub>2</sub>D<sub>3</sub> in the distal intestine of KO/TG mice (KO/TG line 1, noted as TG1) which express  
143 VDR exclusively in the distal intestine (distal ileum, cecum and colon) (14; **Fig. 1A, B**). We  
144 focused on the colon as a possible unappreciated target for regulation of calcium homeostasis. As  
145 noted in **Fig. 1C** the classic 1,25(OH)<sub>2</sub>D<sub>3</sub> activated genes in the proximal intestine were also the  
146 genes most markedly induced by 1,25(OH)<sub>2</sub>D<sub>3</sub> in the colon of the TG mice (*Cyp24a1*, *Trpv6* and  
147 *Sl00g*). Induction of *Sl00g*, *Trpv6* as well as *Atp2b*, genes involved in active calcium transport  
148 (1), suggests that active calcium transport in the distal intestine is involved in the normalization  
149 of mineral homeostasis in these mice. Genes associated with passive calcium transport, *Cldn2*,  
150 *Cldn12* or *Cacna1d* (Cav1.3 gene) and *Trpm7* which have been suggested as channels other than  
151 *Trpv6* for regulation of intestinal calcium absorption (6,24,25), were not significantly regulated  
152 by 1,25(OH)<sub>2</sub>D<sub>3</sub> in the colon. In addition to the classic 1,25(OH)<sub>2</sub>D<sub>3</sub> activated genes, *Slc30a10*, a  
153 manganese efflux transporter located in the apical/luminal domain, was also one of the genes  
154 most induced by 1,25(OH)<sub>2</sub>D<sub>3</sub> and was the principal *Slc* transporter gene affected by  
155 1,25(OH)<sub>2</sub>D<sub>3</sub>. Other *Slc* transporters (*Slc30a1* (a Zn transporter) as well as *Slc30a4* and *Slc30a5*  
156 (also Zn transporters; not shown), *Slc39a14* (a Mn transporter which mediates Mn reuptake from  
157 the basolateral membrane) and *Slc37a2* (a phosphate linked glucose 6 phosphate antiporter) were

158 not significantly affected by 1,25(OH)<sub>2</sub>D<sub>3</sub>. RT-PCR analysis of intestinal tissues from the same  
159 transgenic mouse line (KO/TG1) (**Fig. 2A**) as well as from a second independent KO/TG line  
160 (KO/TG2, noted as TG2) (**Fig. 2B**) validated the RNA-seq analyses indicating that the genes  
161 most responsive to 1,25(OH)<sub>2</sub>D<sub>3</sub> in the distal intestine of KO/TG mice include *Cyp24a1*, *Trpv6*,  
162 *Sl00g* and *Slc30a10*. Other *Slc* transporters, *Slc30a1* and *Slc37a2* were unaffected by  
163 1,25(OH)<sub>2</sub>D<sub>3</sub> (**Fig. 2**). Due to the expression of VDR only in the distal intestine, the duodenum of  
164 KO/TG mice is unresponsive to 1,25(OH)<sub>2</sub>D<sub>3</sub> (**Fig. 2**; duo).

165

### 166 Regulation of Vitamin D Target Genes in the Intestine

167 In addition to the induction of *Slc30a10* in the distal intestine of transgenic mice, *Slc30a10*  
168 was found to be regulated by 1,25(OH)<sub>2</sub>D<sub>3</sub> in different intestinal segments (duodenum, ileum and  
169 colon) of vitamin D deficient mice similar to other vitamin D target genes (*Cyp24a1*, *Sl00g*).  
170 *Slc37a2* although not regulated by 1,25(OH)<sub>2</sub>D<sub>3</sub> in the distal intestine, was induced by  
171 1,25(OH)<sub>2</sub>D<sub>3</sub> in the duodenum (**Fig. 3**). In addition, in the duodenum expression of *Slc30a4*,  
172 *Slc30a5*, *Slc39a14*, *Trmp7*, *Cldn12* and *Cacna1d*, similar to findings in the colon (**Fig. 1**) was  
173 unaffected by 1,25(OH)<sub>2</sub>D<sub>3</sub> treatment of vitamin D deficient mice (n = 4, vehicle vs.  
174 1,25(OH)<sub>2</sub>D<sub>3</sub> treated; *p* > 0.5). *Cldn2*, however was significantly induced by 1,25(OH)<sub>2</sub>D<sub>3</sub> in the  
175 duodenum of these mice (3.8 fold; n=4 vehicle vs. 1,25(OH)<sub>2</sub>D<sub>3</sub> treated; *p* < 0.05).

176 To gain insight into a possible role of the vitamin D in the regulation of Mn transport,  
177 further studies were done comparing the regulation of *Slc30a10* in the intestine to the regulation  
178 of known vitamin D target genes. As shown in **Fig. 4A**, *Slc30a10* and *Trpv6* showed a similar  
179 time course of induction by 1,25(OH)<sub>2</sub>D<sub>3</sub>. Gene expression for these transporters was  
180 significantly induced in the duodenum at 4h after injection and then decreased to control levels at  
181 24 h after 1,25(OH)<sub>2</sub>D<sub>3</sub> administration. Similar findings were observed for *Slc30a10* and *Trpv6*  
182 in colon (data not shown). These findings suggest a rapid response of *Trpv6* and *Slc30a10* to  
183 1,25(OH)<sub>2</sub>D<sub>3</sub> for intestinal calcium or Mn transport.

184 In addition to regulation by 1,25(OH)<sub>2</sub>D<sub>3</sub>, effects of dietary calcium on the expression of  
185 these genes was also examined. Four-week-old mice were fed either a high calcium (1%) or low  
186 calcium diet (0.02%) diet for 4 weeks. As shown in **Fig. 4B**, under conditions of low dietary  
187 calcium (which results in increased circulating 1,25(OH)<sub>2</sub>D<sub>3</sub> levels) (1) an induction in both  
188 *Slc30a10* and *Trpv6* is observed in the duodenum. A similar induction of these genes in response

189 to low dietary calcium was also observed in the colon (not shown). *S100g* was also significantly  
190 increased in duodenum and colon in response to low dietary calcium (data not shown). These  
191 findings suggest coregulation of these manganese and calcium transporters under conditions of  
192 dietary calcium alteration.

193 In additional studies developmental changes in the expression of *Slc30a10* and *Trpv6*  
194 were compared. *Trpv6* was not expressed significantly in the intestine until after birth and was  
195 induced at three weeks of age, the time of weaning in mice which coincides with the increase in  
196 active intestinal calcium transport (**Fig. 4C**) (26). Unlike *Trpv6*, *Slc30a10* was detected in the  
197 fetal intestine. The most marked induction in the expression of *Slc30a10* was observed between  
198 the expression in fetal intestine and at one week postpartum. Thus, developmental changes in  
199 intestinal *Slc30a10* and *Trpv6* do not coincide, suggesting that different factors modulate the  
200 developmental expression of these transporters.

201 To further understand a possible interrelationship between vitamin D and manganese  
202 homeostasis, vitamin D target genes associated with  $1,25(\text{OH})_2\text{D}_3$  mediated calcium transport  
203 were examined in the intestine of the *Slc30a10*<sup>-/-</sup> mouse which has manganese levels in blood,  
204 brain and liver 20-60 fold higher than controls (27). Expression of *S100g* and *Trpv6* was  
205 markedly decreased in the duodenum of the *Slc30a10*<sup>-/-</sup> mice (> 10-fold **Fig. 5A**) but not  
206 significantly changed in the colon. Also, no change was observed in the duodenum and colon in  
207 the expression of *Tjp1* (ZO-1 gene; previous reports suggested regulation by  $1,25(\text{OH})_2\text{D}_3$  of  
208 intestinal tight junction protein ZO-1) (28). In order to determine the specificity for vitamin D  
209 regulated calcium transporters in the intestine, *Trpv5* and *S100g* were examined in the kidney of  
210 the *Slc30a10*<sup>-/-</sup> mice. *S100g* and *Trpv5* were unaffected in the kidney (**Fig. 5B**).

211 Micro-computed tomography ( $\mu\text{CT}$ ) analysis of the tibiae was performed to assess  
212 trabecular and cortical parameters in control and *Slc30a10*<sup>-/-</sup> mice. Trabecular bone mass was  
213 slightly, although not significantly, reduced in male *Slc30a10*<sup>-/-</sup> mice versus control mice,  
214 whereas no differences in trabecular bone mass were observed in female mice (**Table 1**).  
215 However, a strong cortical bone phenotype was observed in both male and female mice. Tibias  
216 of *Slc30a10*<sup>-/-</sup> mice were smaller in diameter than tibias of control mice as evidenced by their  
217 reduced cross-sectional tissue area. In addition, cortical thickness as well as cortical porosity  
218 were significantly reduced in *Slc30a10*<sup>-/-</sup> mice at the mid-diaphysis (**Table 1**). Serum calcium  
219 levels were unchanged between *Slc30a10*<sup>-/-</sup> and control mice ( $12.5 \pm 1.3$  vs.  $12.3 \pm 0.4$  ng/ml

220 respectively;  $n = 5$  ,  $p > 0.5$ ) Thus, in addition to the reduction in *Trpv6* and *Sl00g*, there is a  
221 significant bone phenotype in these mice.

### 222 **VDR and Vitamin D Target Genes in Mouse Crypts and Villi and in Differentiated and** 223 **Undifferentiated Human Enteroids**

224 To provide insight into the mechanisms involved in the regulation of vitamin D target genes  
225 in the intestine, including the ion transporters, we examined both mouse villi and crypts.  
226 Additionally, human enteroid cultures were used to examine both undifferentiated (crypt-like)  
227 and differentiated (villus-like) responses to  $1,25(\text{OH})_2\text{D}_3$  and to determine whether the effects of  
228  $1,25(\text{OH})_2\text{D}_3$  in the intestine observed in mice are conserved in humans. Although the  
229 importance of vitamin D regulated proteins in intestinal villi has been reported, little is known  
230 about effects of  $1,25(\text{OH})_2\text{D}_3$  in crypts and few findings related to human intestinal VDR targets  
231 have been reported. Crypts and villi were isolated from mouse duodenum using the EDTA  
232 chelation method (**Fig. 6A**). Expression of *Vdr* as well as VDR protein in mouse villus and crypt  
233 was equivalent (**Fig. 6B**). Both villus and crypt respond to  $1,25(\text{OH})_2\text{D}_3$  by inducing expression  
234 of *Cyp24a1* (**Fig. 6C**). *Slc30a10* and *Trpv6*, although more pronounced in villi were also  
235 expressed in crypts of WT mice (**Fig. 6D**).

236 RNA-seq analysis of human duodenal enteroids (**Fig. 7A-C**) showed that intestinal vitamin D  
237 target genes are conserved in humans. Similar to the findings in mice, expression of *VDR* under  
238 basal conditions was equivalent in villus and crypt compartments. The expression of *VDR* was  
239 not significantly affected by  $1,25(\text{OH})_2\text{D}_3$ . However, *TRPV6*, *SLC30a10*, *CYP24A1* and *ATP2B1*  
240 were significantly upregulated upon  $1,25(\text{OH})_2\text{D}_3$  treatment in both villus and crypt (**Fig. 7C**).  
241 *Sl00G* was significantly induced by  $1,25(\text{OH})_2\text{D}_3$  only in villus like cultures. A similar  
242 regulation of vitamin D targets genes was observed in crypt-like and villus-like human enteroids  
243 derived from the colon (data not shown). Gene expression of *Slc* transporters in addition to  
244 *SLC30A10* in differentiated and undifferentiated human duodenal enteroids treated with  
245  $1,25(\text{OH})_2\text{D}_3$  or vehicle is shown in **Table 2**. *SLC30A4* and *SLC30A5* were not significantly  
246 affected by  $1,25(\text{OH})_2\text{D}_3$ . *SLC37A2* was induced in villus but not in crypts. The intestinal  
247 phosphate transporter, *SLC34A2*, was upregulated by  $1,25(\text{OH})_2\text{D}_3$  in both villus and crypt.  
248 *TRPM7*, a non-*Slc* transporter, was unaffected by  $1,25(\text{OH})_2\text{D}_3$  treatment. Gene Ontology (GO)  
249 analysis was performed to identify biological processes, cellular components and molecular



250 function terms that are enriched in human duodenal enteroids treated with 1,25(OH)<sub>2</sub>D<sub>3</sub>. The  
251 enrichment score [-log<sub>10</sub> (p value)] of the terms were plotted to indicate the significance of the  
252 enrichment of each function. Regulation of epithelial cell differentiation represented a major  
253 category for enrichment of genes by 1,25(OH)<sub>2</sub>D<sub>3</sub> in crypts (**Fig. 8**). Sonic hedgehog (*SHH*),  
254 which controls the proliferation of stem cells, was a 1,25(OH)<sub>2</sub>D<sub>3</sub> target gene in this ontology  
255 group as well as response to nutrient, cell migration and cell motility, indicating a role for  
256 1,25(OH)<sub>2</sub>D<sub>3</sub> in the function of stem cells. Pathway analysis indicated enrichment of genes by  
257 1,25(OH)<sub>2</sub>D<sub>3</sub> involved ion transport, oxidation reduction, vitamin D 24-hydroxylase activity,  
258 steroid metabolic processes, as well as calcium ion binding and microsomes and vesicular  
259 fraction were categories shared in both villus and crypt (**Fig. 8**). 1,25(OH)<sub>2</sub>D<sub>3</sub> target gene  
260 members of the gene ontology group identifying microsomes and vesicular fraction include  
261 CYP3A4 which is involved in vitamin D metabolism and CYP2C19 and CYP2C18 involved in  
262 drug metabolism.

263

## 264 Discussion

265

266 Vitamin D plays a major role in maintaining the integrity and function of the intestine as  
267 well as in the control of calcium homeostasis. However, the mechanisms by which 1,25(OH)<sub>2</sub>D<sub>3</sub>  
268 regulates these processes are not fully understood. Our findings indicate the importance of the  
269 distal as well as the proximal segments of the intestine to understand the intestinal effects of  
270 1,25(OH)<sub>2</sub>D<sub>3</sub> and that 1,25(OH)<sub>2</sub>D<sub>3</sub> mediated responses involve epithelial cells in the crypts as  
271 well as the villus. This study also shows that the effects of 1,25(OH)<sub>2</sub>D<sub>3</sub> on intestine are complex,  
272 are conserved in humans for active calcium uptake and include calcium regulating as well as  
273 calcium independent effects in both proximal and distal intestine.

274

275 Previous investigations reported that 1,25(OH)<sub>2</sub>D<sub>3</sub> mediated active calcium transport was  
276 localized only in the duodenum where the most pronounced effects of 1,25(OH)<sub>2</sub>D<sub>3</sub> during the  
277 active calcium transport process were induction of calbindin-D9k (*S100g*) and *Trpv6* (4,5,9).  
278 Our current findings indicate that the classic 1,25(OH)<sub>2</sub>D<sub>3</sub> activated genes (*S100g* and *Trpv6*) are  
279 also the two genes most markedly induced by 1,25(OH)<sub>2</sub>D<sub>3</sub> in the distal intestine (similar to  
280 previous findings in the proximal intestine). In addition, our recent study showing for the first

281 time a similar VDR-dependent calcium absorption efficiency between proximal colon and  
282 duodenum in the same mouse further establishes a role for the distal intestine in VDR-mediated  
283 intestinal calcium absorption (29). In that study calcitriol glycosides and glucuronides, which  
284 target calcium absorption in the distal intestine, were also found to upregulate *Trpv6* and *S100g*  
285 (the genes involved in active calcium transport) as well as calcium absorption in the colon. These  
286 results which provide direct in vivo evidence for the importance of VDR in the distal intestine,  
287 suggest, together with earlier studies (11-14), that active calcium transport is a vitamin D-  
288 dependent process in the distal intestine which plays a role in calcium homeostasis. Calcitriol  
289 glucuronide treatment may be a potential means to target calcitriol to the distal intestine and thus  
290 compensate for the loss of calcium absorption for example by gastric bypass surgery or small  
291 bowel resection. In the current investigation, specific genes previously associated with  
292 paracellular calcium transport were not significantly changed by  $1,25(\text{OH})_2\text{D}_3$  in mouse distal  
293 intestine. However, *Cldn2* was significantly induced by  $1,25(\text{OH})_2\text{D}_3$  in the duodenum. Although  
294 it is possible that  $1,25(\text{OH})_2\text{D}_3$  may be involved in paracellular as well as active calcium  
295 transport, the physiological relevance of the reported regulation of genes by  $1,25(\text{OH})_2\text{D}_3$   
296 involved in paracellular transport remains to be determined (6,7,18).

297

298 As compared to other tissues, the highest levels of VDR are found in the small and large  
299 intestine. Studies related to  $1,25(\text{OH})_2\text{D}_3$  mediated responses have focused on effects in  
300 differentiated enterocytes and have supported a role for  $1,25(\text{OH})_2\text{D}_3$  in intestinal calcium  
301 absorption as well as barrier function (4-7). However, the effect of  $1,25(\text{OH})_2\text{D}_3$  on intestinal  
302 stem cells has not been well investigated and has been a matter of debate (20-22). Previous  
303 studies using oral treatment, reported that  $1,25(\text{OH})_2\text{D}_3$  stimulates *Cyp24a1* in intestinal  
304 epithelial cells at the villus or tip region and not at the crypts (20). Early microscopic  
305 autoradiographic studies however noted that tritium labeled  $1,25(\text{OH})_2\text{D}_3$  concentrated in both  
306 absorptive and crypt epithelial cells in small and large intestine (30,31). Using a highly specific  
307 and sensitive VDR antibody (D6) (32), we also noted, similar to the autoradiographic studies,  
308 that VDR is present in villus and crypts. Our studies using isolated mouse villus and crypt as  
309 well as human enteroids with either a crypt-like phenotype (high proliferation, undifferentiated)  
310 or a villus-like phenotype (low proliferation, differentiated) identified  $1,25(\text{OH})_2\text{D}_3$  induced  
311 target genes, including *Cyp24a1*, in both villus and crypts. The importance of vitamin D in the

312 function of Lgr5+ stem cells which are sensitive to Wnt stimulation and contribute to intestinal  
313 homeostatic regeneration, was previously noted by L. Augenlicht's lab (22). They showed that  
314 inactivation of the VDR in mouse Lgr5+ intestinal crypt base columnar cells compromised stem  
315 cell functions of the Lgr5+ cells (22). Studies in human colon crypt organoids have also provided  
316 evidence that VDR is expressed in intestinal stem cells and has a regulatory role as 1,25(OH)<sub>2</sub>D<sub>3</sub>  
317 was found to induce stemness-related genes and to inhibit genes involved in cell proliferation  
318 (33). We are now only beginning to understand the regulatory role of vitamin D in intestinal  
319 stem cells (22,33,34). It is of interest that both in our *in vivo* studies in mice as well as in our  
320 studies using human enteroids, 1,25(OH)<sub>2</sub>D<sub>3</sub> was found to regulate classic target genes in both  
321 villus and crypt. These findings suggest, similar to early studies showing the time dependency of  
322 1,25(OH)<sub>2</sub>D<sub>3</sub> action in enterocytes during their differentiation (35), that 1,25(OH)<sub>2</sub>D<sub>3</sub> action in  
323 the intestine involves not only calcium absorption but also cellular differentiation and intestinal  
324 homeostasis. Although there have been many studies related to the intestinal effects of vitamin  
325 D in animals, our findings are one of the few studies examining human vitamin D target genes.  
326 Previous studies have been done using human intestinal cell lines derived from colon (19,36-38)  
327 as well as human biopsies and duodenal explants (39,40). The limitation of the studies in  
328 explants is the inability of the cells to renew as well as cell death in the explants. The enteroid  
329 culture system from human tissue allows for growth and maintenance over time and provides an  
330 important *in vitro* model to examine both stem and non-stem cell responses to 1,25(OH)<sub>2</sub>D<sub>3</sub>.  
331 These epithelial cultures of the intestinal tract will provide technology enabling the verification  
332 of findings observed in animals and the identification of key components involved in  
333 1,25(OH)<sub>2</sub>D<sub>3</sub> action in human intestinal biology.

334

335 In addition to *Cyp24a1*, *Trpv6* and *SI00g*, *Slc30a10*, a manganese efflux transporter is  
336 also a 1,25(OH)<sub>2</sub>D<sub>3</sub> target gene in both proximal and distal intestine. Slc30a10 is localized in the  
337 apical/luminal domain of the intestine, in liver and brain (41). Although initially thought to act as  
338 a Zn efflux transporter, recent studies have identified SLC30A10 as a mediator of Mn efflux  
339 which lowers cellular Mn levels and protects against Mn toxicity (23,27,42,43). In clinical  
340 studies, patients carrying homozygous mutations in *SLC30A10* show enhanced Mn levels,  
341 neurotoxicity and liver injury (43,44). It is of interest that Mn levels in the brain are minimally  
342 elevated in liver specific Slc30a10 KO mice (41,45). However endoderm specific KO mice

343 (lacking *Slc30a10* in liver and the gastrointestinal tract) were found to have markedly elevated  
344 Mn levels in the brain, indicating a critical role for the digestive system in the regulation of brain  
345 manganese (41,45). Our results suggest that 1,25(OH)<sub>2</sub>D<sub>3</sub>, by inducing *Slc30a10* in the intestine,  
346 may increase Mn excretion and thus may have therapeutic benefit without direct effects on the  
347 brain. Preliminary data comparing mice injected with MnCl<sub>2</sub> (15 µg/g bw) alone or MnCl<sub>2</sub> +  
348 1,25(OH)<sub>2</sub>D<sub>3</sub> (1ng/g bw) 3 times per week for 3 week showed that 1,25(OH)<sub>2</sub>D<sub>3</sub> treatment results  
349 in decreased levels of blood Mn (control 30 ± 2.3; Mn, 403 ± 91; Mn ± 1,25(OH)<sub>2</sub>D<sub>3</sub>, 288 ± 3.3  
350 ng Mn/ml; S. Mukhopadhyay and S. Christakos, preliminary results). Further studies will be  
351 needed to determine effects of 1,25(OH)<sub>2</sub>D<sub>3</sub> on neurotoxicity, on levels of Mn in different tissues  
352 as well as effects of vitamin D deficiency, dietary calcium and high dose dietary vitamin D on  
353 Mn toxicity. Although elevated levels of Mn are neurotoxic, Mn is an essential element which  
354 plays a role in many cellular processes (46). With regard to bone homeostasis, it has been  
355 reported that the skeleton is positively influenced by Mn and that deficiency in Mn affects bone  
356 mass. Studies in rats have shown that Mn supplementation inhibits ovariectomy induced bone  
357 loss (47). In addition, plasma levels of Mn were reported to be significantly decreased in groups  
358 of osteoporotic patients (48). More recent studies have noted that local manganese chloride  
359 treatment accelerates fracture healing in a rat model (49). However, excess of Mn can adversely  
360 affect bone quality. In our study using the *Slc30a10* global KO mouse, which exhibits marked  
361 elevations in blood Mn, significant cortical bone abnormalities were noted. These findings  
362 further indicate the importance of maintaining Mn levels at an optimal range and not exceeding  
363 the levels required to accomplish essential functions. The mechanisms involved in the adverse  
364 effects on bone observed in the *Slc30a10* KO mouse are not known. Whether the reduced  
365 thyroxine production observed in the *Slc30a10* KO mouse plays a role in the bone phenotype  
366 remains to be determined (50). The precise mechanism whereby Mn affects thyroxine  
367 biosynthesis is not known. It is of interest that a patient with a loss of function of *SLC30A10*  
368 mutation was also identified with hypothyroidism (51).

369

370 Due to the necessity of maintaining Mn levels in a narrow range in order to prevent  
371 toxicity, understanding the regulation of *SLC30A10* is critical. The regulation of *Slc30a10* in the  
372 intestine by 1,25(OH)<sub>2</sub>D<sub>3</sub> suggests that 1,25(OH)<sub>2</sub>D<sub>3</sub> not only affects absorption of calcium but  
373 may also affect the transport of other divalent cations. The time course of response to

374 1,25(OH)<sub>2</sub>D<sub>3</sub> showed that expression of *Trpv6* and *Slc30a10* is significantly elevated 4 h after  
375 1,25(OH)<sub>2</sub>D<sub>3</sub>. 24 h after administration of 1,25(OH)<sub>2</sub>D<sub>3</sub> the expression of the genes for both  
376 transporters is decreased to levels observed prior to 0 h, consistent with a rapid response of both  
377 transporters to 1,25(OH)<sub>2</sub>D<sub>3</sub> as previously noted for *Trpv6* expression (52). The early induction  
378 of these transporters would be needed for rapid calcium uptake or Mn efflux. Although putative  
379 vitamin D response elements have been noted in the human and mouse gene which encode  
380 SLC30A10 (18,19), studies are needed to determine VDR binding sites which are functionally  
381 linked to the expression of these genes. The significance of a possible inhibitory effect of  
382 unliganded VDR also requires further studies (53,54).

383 To further understand the role of vitamin D in manganese homeostasis, the expression of  
384 the classic vitamin D target genes was examined in the intestine of the *Slc30a10* KO mouse. In  
385 the *Slc30a10* KO mouse a marked decrease in the expression of *Trpv6* and *S100g* in the  
386 duodenum, a primary route of manganese excretion (55), was consistently observed. These  
387 findings suggest that TRPV6, S100G and SLC30A10 may work together in manganese efflux  
388 transport. Previous studies using HEK cells transfected with human (h) *TRPV6* showed that  
389 TRPV6 is permeable to Mn as well as other heavy metal cations, indicating that TRPV6 is not  
390 only involved in calcium transport (56). Since intracellular calcium concentrations have been  
391 reported to correlate with the level of expression of TRPV6 (56), our findings of a decrease in  
392 *Trpv6* (and *S100g*) in the intestine of mice with *Slc30a10* deficiency and defective Mn excretion  
393 suggest the possibility of intracellular calcium mediated regulation of intestinal *Slc30a10*.  
394 Kovacs et al observed an inhibition of calcium uptake mediated by TRPV6 in the presence of  
395 high concentrations of Mn (56). Therefore, it is also possible that low levels of expression of the  
396 genes involved in calcium homeostasis may be due to the high Mn levels in the *Slc30a10* KO  
397 mice. Although not previously identified *in vivo* in the intestine, an interrelationship between  
398 calcium and Mn transport has been noted in other reports including studies in mast cells, in  
399 mitochondria and in brain (57-62). It has been suggested that Mn may interfere with brain  
400 calcium homeostasis (62). In the mitochondria, Mn transport has been reported to be activated by  
401 calcium (58,60). However calcium transport in the mitochondria is inhibited in the presence of  
402 Mn (58). In recent studies using HEK cells, it was noted that *Slc30a10* extrusion of Mn was  
403 calcium-dependent (63). The authors suggested that *Slc30a10* uses a calcium gradient for active  
404 counter ion exchange (63). Whether Mn efflux transport is regulated in part by calcium in the

405 intestine (as suggested by our findings) and whether intestinal calcium transport is inhibited in  
406 the presence of high blood Mn levels (which are observed in the *Slc30a10* KO mouse) remains to  
407 be determined. It is possible that the role of the distal intestine, where *Slc30a10* is also induced  
408 by  $1,25(\text{OH})_2\text{D}_3$ , may be compensatory when Mn efflux from the proximal intestine is disrupted.  
409 The relationship between calcium, the vitamin D endocrine system and Mn efflux in the intestine  
410 is an unexplored topic. Since the digestive system has recently been identified as a critical  
411 regulator of Mn toxicity (41,45), further studies are needed to provide new insight on the role of  
412 calcium and the vitamin D on Mn homeostasis and protection against neurotoxicity.

413 Findings in our lab as well as prior reports have noted that  $1,25(\text{OH})_2\text{D}_3$  treatment affects  
414 the gene expression of intestinal transporters in addition to *Slc30a10*. Expression of *Slc37a2*,  
415 which encodes a phosphate linked glucose 6 phosphate antiporter, was previously shown to be  
416 induced by  $1,25(\text{OH})_2\text{D}_3$  in mouse intestine (18). Although not regulated by  $1,25(\text{OH})_2\text{D}_3$  in the  
417 mouse distal intestine, we found that *SLC37A2* was induced by  $1,25(\text{OH})_2\text{D}_3$  in human enteroids  
418 from duodenum (**Table 2**) and colon (data not shown). Regulation of *SLC37A2* by  $1,25(\text{OH})_2\text{D}_3$   
419 is not specific to the intestine. *SLC37A2* has also been suggested as a gene target and marker of  
420 vitamin D status in hematopoietic cells (64). Although *SLC37A2* can transport glucose 6  
421 phosphate (G6P), recent findings suggested that *SLC37A2* does not have a role in the regulation  
422 of blood glucose (65). Since the functional role of *SLC37A2* is not understood at this time, the  
423 physiological significance of regulation of gene expression by  $1,25(\text{OH})_2\text{D}_3$  in both mouse and  
424 human intestine remains to be determined. Although we did not find that  $1,25(\text{OH})_2\text{D}_3$  affected  
425 major Zn transporters, previous studies noted regulation of zinc transporters by  $1,25(\text{OH})_2\text{D}_3$  in  
426 mouse intestine (18). Both calcium and zinc are known to play important roles in normal  
427 development and bone homeostasis (66-68). Early studies in chicks, however, noted that vitamin  
428 D or  $1,25(\text{OH})_2\text{D}_3$  does not affect zinc absorption in zinc deficient or replete animals (69). Due  
429 to the importance of zinc as well as calcium for skeletal integrity, further studies are needed to  
430 determine an interrelationship between vitamin D and zinc whether vitamin D has an effect on  
431 zinc homeostasis. In addition to regulation of *SLC30A10* as well as *SLC37A2*, *SLC34A2*, the  
432 intestinal cotransporter NaPi-IIb was noted to be a gene target induced by  $1,25(\text{OH})_2\text{D}_3$  in human  
433 enteroids derived from duodenum (*SLC34A2* is expressed in the proximal intestine in humans  
434 and primarily in the ileum in mice).  $1,25(\text{OH})_2\text{D}_3$  is known to stimulate intestinal phosphate  
435 absorption (70) and *SLC34A2* has been reported to protect bone when dietary phosphate is

436 restricted (71). However, the role of  $1,25(\text{OH})_2\text{D}_3$  in the regulation of intestinal SLC34A2 (NaPi-  
437 IIb) has been a matter of debate (72-74). Further studies are needed to examine the regulation of  
438 this phosphate transporter in human intestine, its physiological significance in bone and  
439 phosphate homeostasis in man and whether it has a role in the dysregulation of phosphate  
440 observed in chronic kidney disease.

441 In a recent study intestine specific knockout of *Trpm7*, which encodes a channel kinase  
442 suggested to control magnesium levels, resulted in decreased serum zinc and calcium levels as  
443 well as decreased serum magnesium by post-natal day 5 (mice died by post-natal day 10) (25).  
444 The authors suggested that TRPM7 is the common gatekeeper for these ions in the intestine and  
445 that TRPM7 and not TRPV6 is the key factor in intestinal calcium absorption. However, these  
446 findings were observed in mice prior to the onset of vitamin D receptor mediated active intestinal  
447 calcium absorption (which occurs at weaning). In addition, results of our transcriptomic analyses  
448 did not indicate regulation of *Trpm7* by  $1,25(\text{OH})_2\text{D}_3$  in the intestine of mice and *TRPM7*  
449 expression was unaffected by  $1,25(\text{OH})_2\text{D}_3$  treatment in human enteroids. Thus, although  
450 TRPM7 is important in early post-natal life, TRPV6 and not TRPM7 is involved in the process  
451 of  $1,25(\text{OH})_2\text{D}_3$  regulated intestinal calcium absorption.

452 In summary, our findings suggest the importance of the distal as well as the proximal  
453 intestinal segments in order to understand intestinal effects of vitamin D and that  $1,25(\text{OH})_2\text{D}_3$   
454 effects involve intestinal epithelial cells in both the villus and crypt. In addition, our findings  
455 show direct transcriptomic responses to  $1,25(\text{OH})_2\text{D}_3$  in human enteroids in both villus and crypt  
456 and that effects observed in mice are conserved in humans. Since SLC30A10 is the first reported  
457 transporter that uses a calcium gradient for active counter ion exchange, our findings suggest that  
458 TRPV6, S100G and SLC30A10 work together in Mn transport and that  $1,25(\text{OH})_2\text{D}_3$  may have a  
459 role not only to maintain calcium homeostasis but also in the cellular homeostasis of other  
460 divalent ions.

461

#### 462 **Experimental procedures**

463 *Animals* – Studies including the use of wild type (C57BL/6J), KO/TG (mice expressing  
464 VDR only in the distal intestine) and *Vdr* knockout (KO) mice were approved by the Rutgers,

465 New Jersey Medical School Animal Care and Use Committee. Mice were maintained in a virus  
466 and parasite-free barrier facility and exposed to a 12h-light, 12h-dark cycle. Food and water were  
467 given *ad libitum*.

468 Transgenic mice expressing VDR only in the distal intestine were generated as previously  
469 described (14) using a 9.5 kb fragment from the CDX2 promoter which directs transgene  
470 expression specially to the distal intestine (75). The pBSKS-9.5kb CDX2-human(h)VDR poly A  
471 transgene was injected into pronuclei of fertilized mouse oocyte at the Rutgers New Jersey  
472 Medical School Genome Editing Core Facility. Mice heterozygous for transgene integration and  
473 ablation of the endogenous VDR (TG<sup>+/-</sup>, KO<sup>+/-</sup>) were bred to obtain mice with distal intestine  
474 specific hVDR expression (TG/KO mice) (Fig. 1A). All TG/KO mice were fed with standard  
475 rodent chow diet (Rodent Laboratory Chow 5001; Ralston Purina Co.) and were used at 12- 14  
476 weeks of age. Genotyping was performed by PCR using DNA extracted from tail biopsies and  
477 mouse and human specific VDR primers (14). VDR KO mice were obtained from the Jackson  
478 Laboratory (originally from M. Demay, Harvard Medical School).

479 Findings in the TG/KO mouse intestine were compared to results obtained using vitamin  
480 D deficient mice. To examine the response to 1,25(OH)<sub>2</sub>D<sub>3</sub> in both TG/KO mice and vitamin D-  
481 deficient mice, each animal was administered three intraperitoneal injections of vehicle or  
482 1,25(OH)<sub>2</sub>D<sub>3</sub> (Cayman Chemical Company, Ann Arbor, MI) at a concentration of 1 ng/g body  
483 weight (bw) in a 9:1 mix of propylene glycol and ethanol at 48, 24 and 6 hours before  
484 termination. The three-dose protocol was used to study short-term and long-term effects of  
485 1,25(OH)<sub>2</sub>D<sub>3</sub> administration.

486 The vitamin D-deficient mice were generated from C57BL/6J female mice fed a vitamin  
487 D deficient diet (-D, 0.47%Ca, 0.3%P; TD89123; Teklad diet from Envigo) for 3-4 weeks before  
488 mating, during pregnancy and lactation. Their offspring were provided the same diet starting  
489 directly after weaning until the tissues were harvested at 12-14 weeks of age.

490 Slc30a10 KO (*Slc30a10*<sup>-/-</sup>) mice were generated in the lab of Somshuvra Mukhopadhyay  
491 as previously described (27). Tissues from *Slc30a10*<sup>-/-</sup> mice were obtained at the University of  
492 Texas (UT) at Austin under protocols approved by the Institutional Animal Care and Use  
493 Committee at UT Austin. Animals were fed regular rodent chow containing ~84 ug Mn/g chow



494 and tissues harvested at 5-6 weeks as knockouts develop severe Mn toxicity beyond 8 weeks of  
495 age.

496 In order to compare the regulation of *Slc30a10* to the regulation of classic  $1,25(\text{OH})_2\text{D}_3$   
497 target genes a time course of response to  $1,25(\text{OH})_2\text{D}_3$  as well as the response to high or low  
498 calcium diets and developmental changes in the expression of *Slc30a10* were examined. The  
499 time course study was conducted using vitamin D-deficient mice injected with a single dose of  
500  $1,25(\text{OH})_2\text{D}_3$  (ip 10 ng/g bw) and killed at 1,4 or 24h after injection. The dietary study was done  
501 using 4-week-old mice fed either a high calcium (1% Ca, TD92309) or low calcium (0.02% Ca  
502 TD86162) for 4 weeks. For the developmental study time pregnant, neonatal and adult mice were  
503 fed a standard chow diet. Intestine was harvested from 18-day-old fetus and 1-, 3-, and 6-week-  
504 old mice (n = 5-6 per group for 1-, 3- and 6-week-old mice; for fetus n = 3 pooled intestinal  
505 samples of 3 individual intestines). For the mice studies both male and female mice were studied.  
506 No sexual dimorphism was observed in the vitamin D target genes at these ages.

507 To determine whether classical as well as novel responses to  $1,25(\text{OH})_2\text{D}_3$  occur in both  
508 villus and crypt, intestinal epithelial cells were isolated from both crypts and villi. The duodenum  
509 from 3-month-old mice was washed in cold phosphate buffered saline (PBS), cut into 1 cm  
510 pieces and rotated in 3 mM EDTA in PBS at 4°C. After vigorous shaking to release the  
511 epithelium, crypts were depleted of contaminating villi by passing through a 70  $\mu\text{m}$  cell strainer  
512 (BD Falcon, Tewksbury, MA). Villus epithelium was collected from the top of the 70  $\mu\text{m}$  cell  
513 strainer (76). To test whether VDR target genes are conserved in humans, human enteroid  
514 cultures were used with either a crypt-like phenotype (ie high proliferation, undifferentiated  
515 cells) or a villus like phenotype (ie. low proliferation, differentiated cells). Human intestinal  
516 tissue specimens were obtained from endoscopy biopsy performed at Baylor College of  
517 Medicine (BCM) from adult patients of both sexes (3 females and 3 males; before endoscopy  
518 biopsies informed consent was obtained from the patient and the Institutional Review Board at  
519 BCM approved this study). Crypts were isolated using the EDTA chelation method described  
520 above. For human enteroids crypts were resuspended in Matrigel and plated in a 24 well plate.  
521 Enteroids were maintained in complete media with growth factors, CMGF+ with media changes  
522 every 2-3 days (77). Enteroids were split every week by passing them through an insulin syringe  
523 and replated in Matrigel. For treatment of enteroids with  $1,25(\text{OH})_2\text{D}_3$  or vehicle, enteroids were

524 maintained in high Wnt3A (undifferentiated) medium (CMGF+) or differentiation medium  
525 (CMGF+ without Wnt3A, nicotinamide, SB202 and R-Spondin) 3 days before treatment, with  
526 one media change between (77). Subsequently enteroids were treated with 100 nM 1,25(OH)<sub>2</sub>D<sub>3</sub>  
527 (Cayman Chemical Company) or vehicle (ethanol) at equal volumes in media. 24h following  
528 treatment enteroids were collected and processed

529 *RNA isolation and expression analysis* – Total RNA was isolated from mouse tissues,  
530 isolated mouse villus and crypt epithelium and human organoids using RiboZol RNA extraction  
531 reagent (Amresco, Solon, OH) or TRIzol reagent (Invitrogen, Carlsbad, CA) according to  
532 manufacturer's instructions and subsequently purified with RNeasy Plus Universal Kit (Qiagen,  
533 Hilden, Germany) using on column DNase digestion (Qiagen, Hilden, Germany). RNA  
534 concentration was measured with a NanoDrop spectrophotometer ND-1000 (Isogen Life  
535 Science, Utrecht, The Netherlands). RNA integrity was assessed using a denaturing agarose gel  
536 stained with ethidium bromide (EtBr) or by using an Agilent (Agilent Technologies, Santa Clara,  
537 CA) Bioanalyzer nanochip. For quantitative real time PCR (qRT-PCR), 2 µg of total RNA were  
538 used to synthesize complementary DNA using Superscript III First Strand synthesis system  
539 (Invitrogen, Carlsbad, CA) following the manufacturer's instructions. Relative quantification of  
540 target gene expression was performed using Taqman analyses. Taqman Gene Expression Probes  
541 (Applied Biosystems, Foster City, CA) used for qRT-PCR are the following: *Cyp24a1*  
542 (Mm00487244-m1), *S100g* (Mm00486654-m1), *Slc30a1* (Mm00437377\_m1), *Slc30a10*  
543 (Mm00437377-m1), *Slc37a2* (Mm00451435\_m1), *Trpv5* (Mm01166037\_m1), *Trpv6*  
544 (Mm00499069-m1) and *Tjp1* (ZO-1 gene; Mm01320638\_m1). Reactions were performed in a  
545 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA). The cycle steps were as  
546 follow: an initial 3-min incubation at 95 °C, followed by 40 cycles of 95 °C for 10 s, 60 °C for  
547 30 s, and 72 °C for 30 s. Expressions of gene of interest were normalized to *Gapdh* (Mm999999-  
548 g1). The  $2^{-\Delta\Delta C_t}$  method was used to calculate relative gene expression.

549 For global assessment of mouse RNA levels, total RNA was subjected to two rounds of  
550 poly(A) selection using oligo-d(T)25 magnetic beads (New England Biolabs (NEB), Ipswich,  
551 MA) Illumina compatible RNA-seq libraries were constructed using the NEBNext® Ultra™ II  
552 RNA Library Prep with Sample Purification Beads (Catalog no. E7775) and NEBNext®  
553 Multiplex Oligos for Illumina® (Dual Index Primers Set 1; Catalog No. E7600) according to the

554 manufacturer's instructions. Poly A selection and library quality were assessed using TapeStation  
555 2200 (Agilent Technologies, Santa Clara, CA) and libraries were quantified using Qubit 4.0  
556 fluorometer (ThermoFisher, Waltham, MA). The prepared libraries were sequenced on an  
557 Illumina NextSeq 500 instrument. (Illumina, San Diego, CA). CLC Genomics Workbench 11.0.1  
558 version (<http://www.clcbio.com/products/clc-genomics-workbench/:Qiagen>) was used for RNA-  
559 seq analysis. De-multiplexed fastq files from RNA-Seq libraries were imported into the CLC  
560 software. Bases with low quality were trimmed and reads were aligned to the *Mus musculus*  
561 reference genome build 9 (mm9) using Kallisto. The aligned reads were obtained using the  
562 RNA-Seq Analysis tool CLC Genomics Workbench. Kallisto (version 45) was utilized to  
563 quantify the transcript abundances of the RNA-Seq samples through pseudoalignment, using  
564 single-end reads and an Ensembl mm9 transcriptome build index. The tximport (version 1.14.0)  
565 package (78) was run in R (version 3.6.2) to create gene-level count matrices for use with  
566 DESeq2 (version 1.26) (79) by importing quantification data obtained from Kallisto. DESeq2  
567 was then used to generate transcript levels in each tissue sample. RNA-seq data (GSE 144978)  
568 were deposited in the Gene Expression Omnibus of the National Center for Biotechnology.

569 For global assessment of RNA levels from human enteroids samples, RNA-seq data were  
570 aligned to the reference human genome (hg38) using Kallsito. Subsequently, differential gene  
571 expressions for both mouse and human were assessed using DESeq2 in R and transcript levels  
572 were obtained using a false discovery rate of 0.05 and a cut off of 1.5-fold change. RNA-seq data  
573 (GSE 159811) were deposited in the Gene Expression Omnibus of the National Center for  
574 Biotechnology.

575 For GO term analyses transcript IDS were used with the biomaRt package (version 2.42)  
576 (80) along with RDavidWebService package (version 1.24) (81) as well as DAVID 6.8 (82) to  
577 identify biological processes, cellular components and molecular functions in which input genes  
578 are enriched.

579 *Western blot analysis* – For Western bolt analysis of VDR, total cellular protein was  
580 extracted with a lysis buffer containing 50 mM of Tris-HCl (pH 7.5), 150 mM of NaCl, 0.1%  
581 sodium dodecyl sulfate, 1.0% NP-40, and protease inhibitors. Protein content was measured  
582 using Bradford assay (83) or Reducing Agent and Detergent Compatible Protein Assay (Bio-Rad  
583 Laboratories, Inc., Hercules, CA). 50 µg of denatured protein was subjected to sodium dodecyl

584 sulfate-polyacrylamide gel electrophoresis (4-20% gradient gel; Bio-Rad Laboratories, Inc.,  
585 Hercules, CA) and transferred onto a polyvinylidene difluoride membrane (Bio-Rad  
586 Laboratories, Inc., Hercules, CA) for Western blot analysis using an enhanced chemiluminescent  
587 detection system (Denville Scientific, Inc., Holliston, MA).  $\beta$ -actin immunoblotting was used for  
588 sample normalization. Anti-VDR (D-6) [research Resource Identified (RRID):AB\_628040] and  
589 anti-b-actin (RRID:AB\_626632) as well as secondary antibodies were obtained from Santa Cruz  
590 Biotechnology, Inc. (Dallas, TX).

591 *Bone analysis* –  $\mu$ CT analysis of the left tibiae was performed *ex vivo* using a high resolution  
592 SkyScan 1172 system (50 kV, 200  $\mu$ A, 0.5 mm aluminum filter) to examine trabecular and  
593 cortical bone parameters (84). Serial tomographs, reconstructed from raw data using the cone-  
594 beam reconstruction software (NRecon, v.1.4.4.0; Skyscan), were used to compute trabecular  
595 and cortical parameters, respectively from the proximal metaphyseal and mid-diaphyseal area.  
596 Analysis was performed according to the guidelines of the American Society for Bone and  
597 Mineral Research (85).

598 *Serum analysis* – Serum calcium, assayed using a colorimetric assay (Pointe Scientific, Inc.  
599 Canton Mi), was determined by Heartland Laboratories, Ames, Iowa.

600 *Statistical analysis* – Results are displayed as mean  $\pm$  standard error (SEM). Data were analyzed  
601 using student t-test or ANOVA and additionally with Benjamini and Hochberg in a post-hoc test  
602 to consider significant difference between groups ( $p < 0.05$ ).

603

#### 604 **Acknowledgements**

605 We acknowledge the assistance of M. Aburadi and A. Kyeremateng in certain aspects of this  
606 investigation.

607

#### 608 **Author contributions**

609 SL, SC, SM, NFS, MPV and JCF designed the study. SL, JDLC, SH (UT), ZKC, RA, OPC, JH,  
610 PD, LV performed experiments. SL, SC, SM, NFS, ZKC, MPV, JCF, GC, LV, PD, PS, SH  
611 provided interpretation of results. SL and SC wrote the paper with comments from all authors.

612

#### 613 **Funding and additional information**

614 This study was supported by NIH grant DK112365 (to S.C., M.P.V., J.C.F and N.F.S.) and NIH  
615 grant ESO24812 to S. M. as well as a grant from the FWO:G0A2416N to L.V. and G.C.

616

#### 617 **Conflict of interest**

618 The authors disclose no conflicts

#### 619 **References**

- 620 1. Christakos, S., Dhawan, P., Verstuyf, A., Verlinden, L., and Carmeliet, G. (2016) Vitamin D:  
621 Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. *Physiol Rev* **96**, 365-408
- 622 2. Pike, J. W., Meyer, M. B., Benkusky, N. A., Lee, S. M., St John, H., Carlson, A., Onal, M., and  
623 Shamsuzzaman, S. (2016) Genomic Determinants of Vitamin D-Regulated Gene Expression.  
624 *Vitam Horm* **100**, 21-44
- 625 3. Pike, J. W., and Christakos, S. (2017) Biology and Mechanisms of Action of the Vitamin D  
626 Hormone. *Endocrinol Metab Clin North Am* **46**, 815-843
- 627 4. Christakos, S., Lieben, L., Masuyama, R., and Carmeliet, G. (2014) Vitamin D endocrine system  
628 and the intestine. *Bonekey Rep* **3**, 496
- 629 5. Christakos, S. (2012) Recent advances in our understanding of 1,25-dihydroxyvitamin D(3)  
630 regulation of intestinal calcium absorption. *Arch Biochem Biophys* **523**, 73-76
- 631 6. Fujita, H., Sugimoto, K., Inatomi, S., Maeda, T., Osanai, M., Uchiyama, Y., Yamamoto, Y., Wada,  
632 T., Kojima, T., Yokozaki, H., Yamashita, T., Kato, S., Sawada, N., and Chiba, H. (2008) Tight  
633 junction proteins claudin-2 and -12 are critical for vitamin D-dependent Ca<sup>2+</sup> absorption  
634 between enterocytes. *Mol Biol Cell* **19**, 1912-1921
- 635 7. Kutuzova, G. D., and Deluca, H. F. (2004) Gene expression profiles in rat intestine identify  
636 pathways for 1,25-dihydroxyvitamin D(3) stimulated calcium absorption and clarify its  
637 immunomodulatory properties. *Arch Biochem Biophys* **432**, 152-166
- 638 8. Wasserman, R. H., and Fullmer, C. S. (1995) Vitamin D and intestinal calcium transport: facts,  
639 speculations and hypotheses. *J Nutr* **125**, 1971S-1979S
- 640 9. Pansu, D., Bellaton, C., Roche, C., and Bronner, F. (1983) Duodenal and ileal calcium absorption  
641 in the rat and effects of vitamin D. *Am J Physiol* **244**, G695-700
- 642 10. Lee, D. B., Hu, M. S., Kayne, L. H., Nakhoul, F., and Jamgotchian, N. (1991) The importance of  
643 non-vitamin D-mediated calcium absorption. *Contrib Nephrol* **91**, 14-20
- 644 11. Lee, D. B., Walling, M. M., Levine, B. S., Gafter, U., Silis, V., Hodsman, A., and Coburn, J. W.  
645 (1981) Intestinal and metabolic effect of 1,25-dihydroxyvitamin D3 in normal adult rat. *Am J*  
646 *Physiol* **240**, G90-96
- 647 12. Favus, M. J., Kathpalia, S. C., Coe, F. L., and Mond, A. E. (1980) Effects of diet calcium and 1,25-  
648 dihydroxyvitamin D3 on colon calcium active transport. *Am J Physiol* **238**, G75-78
- 649 13. Auchere, D., Tardivel, S., Gounelle, J. C., Drueke, T., and Lacour, B. (1998) Role of transcellular  
650 pathway in ileal Ca<sup>2+</sup> absorption: stimulation by low-Ca<sup>2+</sup> diet. *Am J Physiol* **275**, G951-956
- 651 14. Dhawan, P., Veldurthy, V., Yehia, G., Hsaio, C., Porta, A., Kim, K. I., Patel, N., Lieben, L.,  
652 Verlinden, L., Carmeliet, G., and Christakos, S. (2017) Transgenic Expression of the Vitamin D  
653 Receptor Restricted to the Ileum, Cecum, and Colon of Vitamin D Receptor Knockout Mice  
654 Rescues Vitamin D Receptor-Dependent Rickets. *Endocrinology* **158**, 3792-3804
- 655 15. Kong, J., Zhang, Z., Musch, M. W., Ning, G., Sun, J., Hart, J., Bissonnette, M., and Li, Y. C. (2008)  
656 Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal  
657 barrier. *Am J Physiol Gastrointest Liver Physiol* **294**, G208-216
- 658 16. Sun, J. (2010) Vitamin D and mucosal immune function. *Curr Opin Gastroenterol* **26**, 591-595

- 659 17. Barbachano, A., Fernandez-Barral, A., Ferrer-Mayorga, G., Costales-Carrera, A., Larriba, M. J.,  
660 and Munoz, A. (2017) The endocrine vitamin D system in the gut. *Mol Cell Endocrinol* **453**, 79-87
- 661 18. Lee, S. M., Riley, E. M., Meyer, M. B., Benkusky, N. A., Plum, L. A., DeLuca, H. F., and Pike, J. W.  
662 (2015) 1,25-Dihydroxyvitamin D3 Controls a Cohort of Vitamin D Receptor Target Genes in the  
663 Proximal Intestine That Is Enriched for Calcium-regulating Components. *J Biol Chem* **290**, 18199-  
664 18215
- 665 19. Claro da Silva, T., Hiller, C., Gai, Z., and Kullak-Ublick, G. A. (2016) Vitamin D3 transactivates the  
666 zinc and manganese transporter SLC30A10 via the Vitamin D receptor. *J Steroid Biochem Mol*  
667 *Biol* **163**, 77-87
- 668 20. Reynolds, C. J., Koszewski, N. J., Horst, R. L., Beitz, D. C., and Goff, J. P. (2019) Localization of the  
669 1,25-dihydroxyvitamin d-mediated response in the intestines of mice. *J Steroid Biochem Mol Biol*  
670 **186**, 56-60
- 671 21. Colston, K. W., Mackay, A. G., Finlayson, C., Wu, J. C., and Maxwell, J. D. (1994) Localisation of  
672 vitamin D receptor in normal human duodenum and in patients with coeliac disease. *Gut* **35**,  
673 1219-1225
- 674 22. Peregrina, K., Houston, M., Daroqui, C., Dhima, E., Sellers, R. S., and Augenlicht, L. H. (2015)  
675 Vitamin D is a determinant of mouse intestinal Lgr5 stem cell functions. *Carcinogenesis* **36**, 25-  
676 31
- 677 23. Mukhopadhyay, S. (2018) Familial manganese-induced neurotoxicity due to mutations in  
678 SLC30A10 or SLC39A14. *Neurotoxicology* **64**, 278-283
- 679 24. Kellett, G. L. (2011) Alternative perspective on intestinal calcium absorption: proposed  
680 complementary actions of Ca(v)1.3 and TRPV6. *Nutr Rev* **69**, 347-370
- 681 25. Mittermeier, L., Demirkhanyan, L., Stadlbauer, B., Breit, A., Recordati, C., Hilgendorff, A.,  
682 Matsushita, M., Braun, A., Simmons, D. G., Zakharian, E., Gudermann, T., and Chubanov, V.  
683 (2019) TRPM7 is the central gatekeeper of intestinal mineral absorption essential for postnatal  
684 survival. *Proc Natl Acad Sci U S A* **116**, 4706-4715
- 685 26. Halloran, B. P., and DeLuca, H. F. (1980) Calcium transport in small intestine during early  
686 development: role of vitamin D. *Am J Physiol* **239**, G473-479
- 687 27. Hutchens, S., Liu, C., Jursa, T., Shawlot, W., Chaffee, B. K., Yin, W., Gore, A. C., Aschner, M.,  
688 Smith, D. R., and Mukhopadhyay, S. (2017) Deficiency in the manganese efflux transporter  
689 SLC30A10 induces severe hypothyroidism in mice. *J Biol Chem* **292**, 9760-9773
- 690 28. Zhang, Y. G., Wu, S., and Sun, J. (2013) Vitamin D, Vitamin D Receptor, and Tissue Barriers.  
691 *Tissue Barriers* **1**
- 692 29. Jiang, H., Horst, R. L., Koszewski, N. J., Goff, J. P., Christakos, S., and Fleet, J. C. (2019) Targeting  
693 1,25(OH)2D-mediated calcium absorption machinery in proximal colon with calcitriol glycosides  
694 and glucuronides. *J Steroid Biochem Mol Biol* **198**, 105574
- 695 30. Stumpf, W. E., Sar, M., Reid, F. A., Tanaka, Y., and DeLuca, H. F. (1979) Target cells for 1,25-  
696 dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. *Science*  
697 **206**, 1188-1190
- 698 31. Stumpf, W. E. (2008) Vitamin D and the digestive system. *Eur J Drug Metab Pharmacokinet* **33**,  
699 85-100
- 700 32. Wang, Y., Zhu, J., and DeLuca, H. F. (2012) Where is the vitamin D receptor? *Arch Biochem*  
701 *Biophys* **523**, 123-133
- 702 33. Fernandez-Barral, A., Costales-Carrera, A., Buirra, S. P., Jung, P., Ferrer-Mayorga, G., Larriba, M.  
703 J., Bustamante-Madrid, P., Dominguez, O., Real, F. X., Guerra-Pastrian, L., Lafarga, M., Garcia-  
704 Olmo, D., Cantero, R., Del Peso, L., Batlle, E., Rojo, F., Munoz, A., and Barbachano, A. (2020)  
705 Vitamin D differentially regulates colon stem cells in patient-derived normal and tumor  
706 organoids. *FEBS J* **287**, 53-72

- 707 34. Li, W., Peregrina, K., Houston, M., and Augenlicht, L. H. (2019) Vitamin D and the nutritional  
708 environment in functions of intestinal stem cells: Implications for tumorigenesis and prevention.  
709 *J Steroid Biochem Mol Biol* **198**, 105556
- 710 35. Wu, J. C., Smith, M. W., and Lawson, D. E. (1992) Time dependency of 1,25(OH)<sub>2</sub>D<sub>3</sub> induction of  
711 calbindin mRNA and calbindin expression in chick enterocytes during their differentiation along  
712 the crypt-villus axis. *Differentiation* **51**, 195-200
- 713 36. Meyer, M. B., Watanuki, M., Kim, S., Shevde, N. K., and Pike, J. W. (2006) The human transient  
714 receptor potential vanilloid type 6 distal promoter contains multiple vitamin D receptor binding  
715 sites that mediate activation by 1,25-dihydroxyvitamin D<sub>3</sub> in intestinal cells. *Mol Endocrinol* **20**,  
716 1447-1461
- 717 37. Wood, R. J., Tchack, L., and Taparia, S. (2001) 1,25-Dihydroxyvitamin D<sub>3</sub> increases the expression  
718 of the CaT1 epithelial calcium channel in the Caco-2 human intestinal cell line. *BMC Physiol* **1**, 11
- 719 38. Fleet, J. C., Eksir, F., Hance, K. W., and Wood, R. J. (2002) Vitamin D-inducible calcium transport  
720 and gene expression in three Caco-2 cell lines. *Am J Physiol Gastrointest Liver Physiol* **283**, G618-  
721 625
- 722 39. Walters, J. R., Balesaria, S., Chavele, K. M., Taylor, V., Berry, J. L., Khair, U., Barley, N. F., van  
723 Heel, D. A., Field, J., Hayat, J. O., Bhattacharjee, A., Jeffery, R., and Poulosom, R. (2006) Calcium  
724 channel TRPV6 expression in human duodenum: different relationships to the vitamin D system  
725 and aging in men and women. *J Bone Miner Res* **21**, 1770-1777
- 726 40. Balesaria, S., Sangha, S., and Walters, J. R. (2009) Human duodenum responses to vitamin D  
727 metabolites of TRPV6 and other genes involved in calcium absorption. *Am J Physiol Gastrointest*  
728 *Liver Physiol* **297**, G1193-1197
- 729 41. Taylor, C. A., Hutchens, S., Liu, C., Jursa, T., Shawlot, W., Aschner, M., Smith, D. R., and  
730 Mukhopadhyay, S. (2019) SLC30A10 transporter in the digestive system regulates brain  
731 manganese under basal conditions while brain SLC30A10 protects against neurotoxicity. *J Biol*  
732 *Chem* **294**, 1860-1876
- 733 42. Leyva-Illades, D., Chen, P., Zogzas, C. E., Hutchens, S., Mercado, J. M., Swaim, C. D., Morrisett, R.  
734 A., Bowman, A. B., Aschner, M., and Mukhopadhyay, S. (2014) SLC30A10 is a cell surface-  
735 localized manganese efflux transporter, and parkinsonism-causing mutations block its  
736 intracellular trafficking and efflux activity. *J Neurosci* **34**, 14079-14095
- 737 43. Tuschl, K., Clayton, P. T., Gospe, S. M., Jr., Gulab, S., Ibrahim, S., Singhi, P., Aulakh, R., Ribeiro, R.  
738 T., Barsottini, O. G., Zaki, M. S., Del Rosario, M. L., Dyack, S., Price, V., Rideout, A., Gordon, K.,  
739 Wevers, R. A., Chong, W. K., and Mills, P. B. (2012) Syndrome of hepatic cirrhosis, dystonia,  
740 polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese  
741 transporter in man. *Am J Hum Genet* **90**, 457-466
- 742 44. Quadri, M., Federico, A., Zhao, T., Breedveld, G. J., Battisti, C., Delnooz, C., Severijnen, L. A., Di  
743 Toro Mammarella, L., Mignarri, A., Monti, L., Sanna, A., Lu, P., Punzo, F., Cossu, G., Willemsen,  
744 R., Rasi, F., Oostra, B. A., van de Warrenburg, B. P., and Bonifati, V. (2012) Mutations in  
745 SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and  
746 chronic liver disease. *Am J Hum Genet* **90**, 467-477
- 747 45. Mercadante, C. J., Prajapati, M., Conboy, H. L., Dash, M. E., Herrera, C., Pettiglio, M. A., Cintron-  
748 Rivera, L., Salesky, M. A., Rao, D. B., and Bartnikas, T. B. (2019) Manganese transporter Slc30a10  
749 controls physiological manganese excretion and toxicity. *J Clin Invest* **129**, 5442-5461
- 750 46. Chen, P., Bornhorst, J., and Aschner, M. (2018) Manganese metabolism in humans. *Front Biosci*  
751 *(Landmark Ed)* **23**, 1655-1679
- 752 47. Rico, H., Gomez-Raso, N., Revilla, M., Hernandez, E. R., Seco, C., Paez, E., and Crespo, E. (2000)  
753 Effects on bone loss of manganese alone or with copper supplement in ovariectomized rats. A  
754 morphometric and densitometric study. *Eur J Obstet Gynecol Reprod Biol* **90**, 97-101

- 755 48. Heaney, R. P. (1988) Nutritional factors in causation of osteoporosis. *Ann Chir Gynaecol* **77**, 176-  
756 179
- 757 49. Hreha, J., Wey, A., Cunningham, C., Krell, E. S., Brietbart, E. A., Paglia, D. N., Montemurro, N. J.,  
758 Nguyen, D. A., Lee, Y. J., Komlos, D., Lim, E., Benevenia, J., O'Connor, J. P., and Lin, S. S. (2015)  
759 Local manganese chloride treatment accelerates fracture healing in a rat model. *J Orthop Res*  
760 **33**, 122-130
- 761 50. Liu, C., Hutchens, S., Jursa, T., Shawlot, W., Polishchuk, E. V., Polishchuk, R. S., Dray, B. K., Gore,  
762 A. C., Aschner, M., Smith, D. R., and Mukhopadhyay, S. (2017) Hypothyroidism induced by loss of  
763 the manganese efflux transporter SLC30A10 may be explained by reduced thyroxine production.  
764 *J Biol Chem* **292**, 16605-16615
- 765 51. Anagianni, S., and Tuschl, K. (2019) Genetic Disorders of Manganese Metabolism. *Curr Neurol*  
766 *Neurosci Rep* **19**, 33
- 767 52. Song, Y., Peng, X., Porta, A., Takanao, H., Peng, J. B., Hediger, M. A., Fleet, J. C., and Christakos,  
768 S. (2003) Calcium transporter 1 and epithelial calcium channel messenger ribonucleic acid are  
769 differentially regulated by 1,25 dihydroxyvitamin D3 in the intestine and kidney of mice.  
770 *Endocrinology* **144**, 3885-3894
- 771 53. Huet, T., Laverny, G., Ciesielski, F., Molnar, F., Ramamoorthy, T. G., Belorusova, A. Y., Antony, P.,  
772 Potier, N., Metzger, D., Moras, D., and Rochel, N. (2015) A vitamin D receptor selectively  
773 activated by gemini analogs reveals ligand dependent and independent effects. *Cell Rep* **10**, 516-  
774 526
- 775 54. Lee, S. M., and Pike, J. W. (2016) The vitamin D receptor functions as a transcription regulator in  
776 the absence of 1,25-dihydroxyvitamin D3. *J Steroid Biochem Mol Biol* **164**, 265-270
- 777 55. Bertinchamps, A. J., Miller, S. T., and Cotzias, G. C. (1966) Interdependence of routes excreting  
778 manganese. *Am J Physiol* **211**, 217-224
- 779 56. Kovacs, G., Danko, T., Bergeron, M. J., Balazs, B., Suzuki, Y., Zsembery, A., and Hediger, M. A.  
780 (2011) Heavy metal cations permeate the TRPV6 epithelial cation channel. *Cell Calcium* **49**, 43-  
781 55
- 782 57. Fasolato, C., Hoth, M., Matthews, G., and Penner, R. (1993) Ca<sup>2+</sup> and Mn<sup>2+</sup> influx through  
783 receptor-mediated activation of nonspecific cation channels in mast cells. *Proc Natl Acad Sci U S*  
784 *A* **90**, 3068-3072
- 785 58. Gavin, C. E., Gunter, K. K., and Gunter, T. E. (1999) Manganese and calcium transport in  
786 mitochondria: implications for manganese toxicity. *Neurotoxicology* **20**, 445-453
- 787 59. Kamer, K. J., Sancak, Y., Fomina, Y., Meisel, J. D., Chaudhuri, D., Grabarek, Z., and Mootha, V. K.  
788 (2018) MICU1 imparts the mitochondrial uniporter with the ability to discriminate between  
789 Ca(2+) and Mn(2+). *Proc Natl Acad Sci U S A* **115**, E7960-E7969
- 790 60. Vinogradov, A., and Scarpa, A. (1973) The initial velocities of calcium uptake by rat liver  
791 mitochondria. *J Biol Chem* **248**, 5527-5531
- 792 61. Ijomone, O. M., Aluko, O. M., Okoh, C. O. A., Martins, A. C., Jr., and Aschner, M. (2019) Role for  
793 calcium signaling in manganese neurotoxicity. *J Trace Elem Med Biol* **56**, 146-155
- 794 62. Bornhorst, J., Wehe, C. A., Huwel, S., Karst, U., Galla, H. J., and Schwerdtle, T. (2012) Impact of  
795 manganese on and transfer across blood-brain and blood-cerebrospinal fluid barrier in vitro. *J*  
796 *Biol Chem* **287**, 17140-17151
- 797 63. Levy, M., Elkoshi, N., Barber-Zucker, S., Hoch, E., Zarivach, R., Hershinkel, M., and Sekler, I.  
798 (2019) Zinc transporter 10 (ZnT10)-dependent extrusion of cellular Mn(2+) is driven by an active  
799 Ca(2+)-coupled exchange. *J Biol Chem* **294**, 5879-5889
- 800 64. Wilfinger, J., Seuter, S., Tuomainen, T. P., Virtanen, J. K., Voutilainen, S., Nurmi, T., de Mello, V.  
801 D., Uusitupa, M., and Carlberg, C. (2014) Primary vitamin D receptor target genes as biomarkers  
802 for the vitamin D3 status in the hematopoietic system. *J Nutr Biochem* **25**, 875-884



- 803 65. Pan, C. J., Chen, S. Y., Jun, H. S., Lin, S. R., Mansfield, B. C., and Chou, J. Y. (2011) SLC37A1 and  
804 SLC37A2 are phosphate-linked, glucose-6-phosphate antiporters. *PLoS One* **6**, e23157
- 805 66. Cousins, R. J. (2010) Gastrointestinal factors influencing zinc absorption and homeostasis. *Int J*  
806 *Vitam Nutr Res* **80**, 243-248
- 807 67. Rossi, L., Migliaccio, S., Corsi, A., Marzia, M., Bianco, P., Teti, A., Gambelli, L., Cianfarani, S.,  
808 Paoletti, F., and Branca, F. (2001) Reduced growth and skeletal changes in zinc-deficient growing  
809 rats are due to impaired growth plate activity and inanition. *J Nutr* **131**, 1142-1146
- 810 68. Lieben, L., Carmeliet, G., and Masuyama, R. (2011) Calcemic actions of vitamin D: effects on the  
811 intestine, kidney and bone. *Best Pract Res Clin Endocrinol Metab* **25**, 561-572
- 812 69. Koo, S. I., Fullmer, C. S., and Wasserman, R. H. (1980) Effect to cholecalciferol and 1,25-  
813 Dihydroxycholecalciferol on the intestinal absorption of zinc in the chick. *J Nutr* **110**, 1813-1818
- 814 70. Williams, K. B., and DeLuca, H. F. (2007) Characterization of intestinal phosphate absorption  
815 using a novel in vivo method. *Am J Physiol Endocrinol Metab* **292**, E1917-1921
- 816 71. Knopfel, T., Pastor-Arroyo, E. M., Schnitzbauer, U., Kratschmar, D. V., Odermatt, A., Pellegrini,  
817 G., Hernando, N., and Wagner, C. A. (2017) The intestinal phosphate transporter NaPi-IIb  
818 (Slc34a2) is required to protect bone during dietary phosphate restriction. *Sci Rep* **7**, 11018
- 819 72. Marks, J. (2019) The role of SLC34A2 in intestinal phosphate absorption and phosphate  
820 homeostasis. *Pflugers Arch* **471**, 165-173
- 821 73. Katai, K., Miyamoto, K., Kishida, S., Segawa, H., Nii, T., Tanaka, H., Tani, Y., Arai, H., Tatsumi, S.,  
822 Morita, K., Taketani, Y., and Takeda, E. (1999) Regulation of intestinal Na<sup>+</sup>-dependent phosphate  
823 co-transporters by a low-phosphate diet and 1,25-dihydroxyvitamin D<sub>3</sub>. *Biochem J* **343 Pt 3**, 705-  
824 712
- 825 74. Capuano, P., Radanovic, T., Wagner, C. A., Bacic, D., Kato, S., Uchiyama, Y., St-Arnoud, R., Murer,  
826 H., and Biber, J. (2005) Intestinal and renal adaptation to a low-Pi diet of type II NaPi  
827 cotransporters in vitamin D receptor- and 1 $\alpha$ OHase-deficient mice. *Am J Physiol Cell Physiol*  
828 **288**, C429-434
- 829 75. Hinoi, T., Akyol, A., Theisen, B. K., Ferguson, D. O., Greenson, J. K., Williams, B. O., Cho, K. R., and  
830 Fearon, E. R. (2007) Mouse model of colonic adenoma-carcinoma progression based on somatic  
831 Apc inactivation. *Cancer Res* **67**, 9721-9730
- 832 76. Chen, L., Vasoya, R. P., Toke, N. H., Parthasarathy, A., Luo, S., Chiles, E., Flores, J., Gao, N.,  
833 Bonder, E. M., Su, X., and Verzi, M. P. (2019) HNF4 Regulates Fatty Acid Oxidation and is  
834 Required for Renewal of Intestinal Stem Cells in Mice. *Gastroenterology*
- 835 77. Mahe, M. M., Sundaram, N., Watson, C. L., Shroyer, N. F., and Helmrath, M. A. (2015)  
836 Establishment of human epithelial enteroids and colonoids from whole tissue and biopsy. *J Vis*  
837 *Exp*
- 838 78. Sonesson, C., Love, M. I., and Robinson, M. D. (2015) Differential analyses for RNA-seq:  
839 transcript-level estimates improve gene-level inferences. *F1000Res* **4**, 1521
- 840 79. Love, M. I., Huber, W., and Anders, S. (2014) Moderated estimation of fold change and  
841 dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550
- 842 80. Durinck, S., Spellman, P. T., Birney, E., and Huber, W. (2009) Mapping identifiers for the  
843 integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat Protoc* **4**, 1184-  
844 1191
- 845 81. Fresno, C., and Fernandez, E. A. (2013) RDAVIDWebService: a versatile R interface to DAVID.  
846 *Bioinformatics* **29**, 2810-2811
- 847 82. Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009) Systematic and integrative analysis of  
848 large gene lists using DAVID bioinformatics resources. *Nat Protoc* **4**, 44-57
- 849 83. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram  
850 quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72**, 248-254

- 851 84. Lieben, L., Benn, B. S., Ajibade, D., Stockmans, I., Moermans, K., Hediger, M. A., Peng, J. B.,  
852 Christakos, S., Bouillon, R., and Carmeliet, G. (2010) Trpv6 mediates intestinal calcium  
853 absorption during calcium restriction and contributes to bone homeostasis. *Bone* **47**, 301-308  
854 85. Bouxsein, M. L., Boyd, S. K., Christiansen, B. A., Guldberg, R. E., Jepsen, K. J., and Muller, R.  
855 (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed  
856 tomography. *J Bone Miner Res* **25**, 1468-1486

857 **Footnotes**

858 The abbreviations used are: 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1,25-dihydroxyvitamin D<sub>3</sub>; 25(OH)D<sub>3</sub>, 25-  
859 hydroxyvitamin D<sub>3</sub>; ANOVA, Analysis of variance; bw, body weight; CYP24A1, 25-  
860 hydroxyvitamin D<sub>3</sub> 24-Hydroxylase; DNA, deoxyribonucleic acid; EDTA,  
861 ethylenediaminetetraacetate; g, gram; HCL, hydrogen chloride; hVDR, human VDR; kb,  
862 kilobases; kDa, kilodaltons; KO, knockout; KO/TG, knockout/transgenic; μCT, micro-computed  
863 tomography; min, minute(s); Mn, manganese; mRNA, messenger RNA; NaPi-IIb, Sodium-  
864 dependent phosphate transport protein 2B; ng, nanogram; PBS, phosphate-buffered saline; RNA-  
865 Seq, RNA sequencing; S100g, RT-qPCR, quantitative reverse transcription PCR; S100 calcium  
866 binding protein G; SEM, standard error of the mean; Slc30a1, zinc transporter 1; SLC30A10,  
867 Solute Carrier Family 30 Member 10; SLC30A4, Solute Carrier Family 30 Member 4;  
868 SLC30A5, solute carrier family 30 member 5; SLC34A2, Sodium-dependent phosphate transport  
869 protein 2B; SLC37A2, Glucose-6-phosphate exchanger; Tris, tris(hydroxymethyl)aminomethane;  
870 TRPV6, Transient receptor potential cation channel subfamily V member 6; VDR, vitamin D  
871 receptor; VDRE, vitamin D response element; Zn, zinc  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895

896

897

898

899

900

901

902

903 **Figure Legends**

904

905 **Figure 1. Gene expression measured by RNA-seq in the colon of KO/TG1 mice treated with**  
906 **1,25(OH)<sub>2</sub>D<sub>3</sub>** (A) KO/TG mice express VDR only in the distal intestine. Expression of hVDR is  
907 restricted to the distal intestine of KO/TG mice. Mouse (m) VDR is absent in KO/TG mice. (B)  
908 Rescue of VDR dependent rickets in the KO/TG mice (Von Kossa staining; see ref 14). (C) Gene  
909 expression in the colon of KO/TG mice treated with 1,25(OH)<sub>2</sub>D<sub>3</sub> (TG1 +D, black bar) compared  
910 to VDR KO (open bar). Gene expression, measured by RNA-seq analysis, is shown as the mean  
911 of RPKM ± SEM. n = 4 per group \*  $p < 0.05$ , TG1 + D compared to VDR KO.

912

913 **Figure 2. Response to 1,25(OH)<sub>2</sub>D<sub>3</sub> treatment in KO/TG mouse intestine as measured by**  
914 **RT-qPCR.** Gene expression in the duodenum (Duo) and colon (Col) of KO/TG1 mice (TG1)  
915 (A) or KO/TG2 mice [mice from a second transgenic line (TG2)] (B) treated with vehicle (black  
916 bar) or 1,25(OH)<sub>2</sub>D<sub>3</sub> (1 ng/g bw at 48, 24 and 6 h before termination; TG1+ D or TG2 + D,  
917 stripped bar). Results are compared to VDR KO mice (open bar). n = 6 per experimental group.  
918 Gene expression was normalized to *Gapdh* and expressed as mean ± SEM (+  $p < 0.05$  compared  
919 to vehicle (TG1 or TG2), #  $p < 0.05$  1,25(OH)<sub>2</sub>D<sub>3</sub> treated (TG1 or TG2 +D) compared to VDR  
920 KO; \*  $p < 0.05$  vehicle (TG1 or TG2) compared to VDR KO. The duodenum was included as a  
921 control. Note the lack of responsiveness of the duodenum to 1,25(OH)<sub>2</sub>D<sub>3</sub> treatment due to the  
922 absence of VDR in the proximal intestine of these transgenic mice. Col, colon; Duo, duodenum;  
923 ND, not detected.

924

925 **Figure 3. Gene expression in intestinal segments in response to repeated administration of**  
926 **1,25(OH)<sub>2</sub>D<sub>3</sub> to vitamin D deficient mice.** 12- to 14-week-old vitamin D-deficient mice were  
927 injected with 1,25(OH)<sub>2</sub>D<sub>3</sub> (+D, black bar) or vehicle (open bar) three times over 48 h (at 48, 24  
928 and 6 h prior to termination (ip. 1ng/g bw per injection). Data was normalized to *Gapdh* and  
929 expressed as mean ± SEM. n = 6 per experimental group. \* Significantly different from vehicle  
930 treated group at  $p < 0.05$ . Duo, duodenum; Ile, ileum; Col, colon; ND, not detected.

931

932 **Figure 4. Regulation of intestinal 1,25(OH)<sub>2</sub>D<sub>3</sub> target gene expression: time course of**  
933 **induction by 1,25(OH)<sub>2</sub>D<sub>3</sub>, effects of dietary calcium and developmental changes.** (A) RT-  
934 qPCR analysis of *Slc30a10* and *Trpv6* expression in the duodenum at 0, 4 and 24 h after a single  
935 injection of 1,25(OH)<sub>2</sub>D<sub>3</sub> (10 ng/g bw) to vitamin D deficient mice. n = 5 per time point. \*  $p <$   
936  $0.05$  compared to 0 time point. (B) RT-qPCR analysis of *Slc30a10* and *Trpv6* expression in  
937 duodenum of mice fed a low calcium (0.02%) or high calcium (1%) diet for 4 weeks. n = 7 per  
938 group. \* Significantly different from the mice fed the high calcium diet at  $p < 0.05$ . (C)  
939 Developmental changes in gene expression in mice raised under standard conditions and killed at

940 18 days gestation and at 1, 3, and 6 weeks of age. Intestine was harvested (for fetus  $n = 5$ , pooled  
941 intestinal samples of 3 - 4 individual intestines;  $n = 5 - 6$  for 1-, 3-, and 6-week-old mice). Since  
942 the small intestine and not individual segments were harvested and analyzed in the fetus, for  
943 comparison small intestine was also analyzed at different post-natal stages. Data are expressed as  
944 mean  $\pm$  SEM. Data were normalized using *Gapdh* or *18S rRNA*. # Significantly different from  
945 fetus at  $p < 0.05$ . \* Significantly different from 1 week old at  $p < 0.05$ . Duo, duodenum.

946

947 **Figure 5. 1,25(OH)<sub>2</sub>D<sub>3</sub> target gene expression in the intestine and kidney of *Slc30a10*<sup>-/-</sup> and**  
948 **control mice.** 1,25(OH)<sub>2</sub>D<sub>3</sub> target genes in the intestine (A) and kidney (B) in *Slc30a10*<sup>-/-</sup> and  
949 control mice. Data are expressed as mean  $\pm$  SEM and were normalized using *Gapdh*.  $n = 4 - 6$  in  
950 each group. \*  $p < 0.05$  significantly different between two experimental groups. Duo, duodenum;  
951 Col, colon.

952

953 **Figure 6. VDR and 1,25(OH)<sub>2</sub>D<sub>3</sub> target genes in mouse epithelial cells in villi and crypts.**  
954 (A) Intestinal epithelial cells were isolated from crypts (left panel) and villi (right panel) of 3-  
955 month-old mouse duodenum. (B) *Vdr* gene expression (left panel) and VDR protein (Western  
956 blot analysis; right panel) in mouse duodenal crypts and villi from 3-month-old WT mice  
957 compared to VDR KO mice. For Western blot analysis the relative optical density (OD) obtained  
958 using the VDR antibody was divided by the OD obtained after  $\beta$ -actin staining to produce VDR-  
959 relative OD.  $n = 3 - 4$  (C and D) RT-qPCR analysis of 1,25(OH)<sub>2</sub>D<sub>3</sub> target genes in mouse  
960 duodenal villi and crypts. (C) *Cyp24a1* expression was examined in 3-month-old mice injected  
961 ip. with vehicle or 1,25(OH)<sub>2</sub>D<sub>3</sub> (1 ng/g bw; injected at 48, 24, and 6 h prior to euthanasia). \*  
962 significantly different from WT + vehicle at  $p < 0.05$ . (D) *Trpv6* and *Slc30a10* gene expression  
963 in intestinal epithelial cells from crypts and villi of 3-month-old WT mice. RT-qPCR reactions  
964 were normalized to *Gapdh* or *18S rRNA*.  $n = 3 - 4$ . ND, not detected.


965


966 **Figure 7. Gene expression measured by RNA-seq in crypt-like and villus-like human**  
967 **duodenal organoids.** (A) Bright field images of crypt-like (undifferentiated) and villus-like  
968 (differentiated) duodenal human enteroids. (B) Venn diagram indicating genes significantly  
969 upregulated at least 1.5 folds and with FDR  $< 0.05$  upon 1,25(OH)<sub>2</sub>D<sub>3</sub> treatment (100 nM for 24  
970 h) in crypt-like (undifferentiated) and villus-like (differentiated) human enteroids and  
971 overlapping genes. (C) Expression counts of *SLC30A10*, *VDR* and classic 1,25(OH)<sub>2</sub>D<sub>3</sub> target  
972 genes in control and 1,25(OH)<sub>2</sub>D<sub>3</sub> treated villus and crypt-like human enteroids. Data is from  
973 enteroids from 6 patients (3 females and 3 males).


974


975

976 **Figure 8. Top GO terms for genes enriched in human duodenal enteroids treated with**  
977 **1,25(OH)<sub>2</sub>D<sub>3</sub>** (A) Crypt only (B) Villus only (C) Crypt and Villus shared.




















**A Intestine****B Kidney**

**A****B****C****D**





**Table 1. Trabecular and Cortical Bone Parameters of control and Slc30a10 KO Mice**

	Male		Female	
	Control	Slc30a10 KO	Control	Slc30a10 KO
<b>Trabecular bone</b>				
<b>N</b>	8	5	10	9
<b>BV/TV (%)</b>	6.55 ± 1.60	4.44 ± 1.29	5.41 ± 2.33	4.72 ± 1.20
<b>Trabecular number (1/mm)</b>	2.07 ± 0.39	1.48 ± 0.36*	1.62 ± 0.57	1.54 ± 0.35
<b>Trabecular thickness (mm)</b>	0.031 ± 0.002	0.030 ± 0.002	0.033 ± 0.002	0.031 ± 0.001*
<b>Cortical bone</b>				
<b>N</b>	8	4	10	8
<b>Cross-sectional tissue area (mm<sup>2</sup>)</b>	2.11 ± 0.30	1.35 ± 0.39*	1.92 ± 0.27	1.33 ± 0.16*
<b>Medullary area (mm<sup>2</sup>)</b>	1.44 ± 0.23	1.00 ± 0.34*	1.29 ± 0.23	1.03 ± 0.13*
<b>Cortical thickness (mm)</b>	0.124 ± 0.012	0.092 ± 0.023*	0.140 ± 0.011	0.086 ± 0.010*
<b>Porosity (%)</b>	12.07 ± 2.68	6.12 ± 1.12*	9.22 ± 2.07	6.24 ± 1.55*

NOTE. Trabecular bone parameters and cortical bone parameters as measured by  $\mu$ CT. Data are presented as mean  $\pm$  SEM (unpaired, two-tailed t test KO vs WT for each sex). BV/TV, bone volume/tissue volume. \* $p < 0.05$ .

**Table 2 Gene expression of transporters in crypt-like and villus-like human enteroids derived from duodenum treated with 1,25(OH)<sub>2</sub>D<sub>3</sub> or vehicle**

Gene	Crypt-like		Villus-like		
	Fold Change	<i>p</i> Value	Fold Change	<i>p</i> Value	
<i>SLC30A10</i>	5.38	2.05E-19*	3.20	2.99E-03*	Mn efflux transporter
<i>SLC30A4</i>	0.82	5.51E-01	0.93	8.44E-01	Zn transporter
<i>SLC30A5</i>	1.02	9.56E-01	1.05	7.89E-01	Zn transporter
<i>SLC34A2</i>	6.94	5.17E-22*	3.02	3.00E-03*	Phosphate transporter
<i>SLC37A2</i>	1.06	9.63E-01	13.13	8.34E-49*	G6P transporter
<i>TRPM7</i>	0.94	9.22E-01	0.78	1.23E-01	non Slc transporter of divalent cations

\**p* < 0.05.